In conclusion, our results show that bortezomib-mediated inhibition of cell proliferation of CML cell lines is associated with down-regulation of SKP2 with concomitant up-regulation/stabilization of p27Kip1. The gene discussed is CDKN1B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.